Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults

Valneva SE VALN reported antibody persistence data 24 months after vaccination with a single dose of its chikungunya vaccine IXCHIQ, further supporting the anticipated long-term durability of the immune response and in line with positive twelve-month persistence data the company reported in December 2022.

Valneva was granted FDA approval for its chikungunya vaccine IXCHIQ in November 2023. 

These persistence data are intended to supplement the existing approval by the FDA and ongoing regulatory approval processes.

97% of the 316 healthy adults still enrolled in the trial retained neutralizing antibody titers above the seroresponse threshold2 twenty-four months after the single-dose vaccination. 

The persistence of antibodies in older adults aged 65 and above was as robust as in younger adults and even slightly higher in terms of geometric mean titers (GMTs) and seroconversion rates (SRRs). 

No safety concerns were identified for the 24-month follow-up, and, as reported in the 12-month data analysis, no Adverse Event of Special Interest was ongoing when participants were enrolled in the trial.

EMA and Health Canada are reviewing the marketing applications with potential approvals in mid-2024. 

A clinical study in adolescents is also ongoing in Brazil, for which the company reported Phase 3 data in November 2023. 

Price Action: VALN shares are down 3.69% at $11.08 on the last check Monday.